DEXCOM INC

DexCom beats earnings, hikes revenue outlook, and boosts CGM demand—see how the G7 launch and global expansion fuel upside and investor confidence.

Dexcom’s Q2 2024 earnings beat Wall Street, with 13% revenue growth and a new FDA‑approved type‑2 diabetes market, positioning the company for higher margins and expanded market share.

Dexcom faces activist pressure from Elliott, urging board upgrades and a strategic review that could boost reimbursement, operational efficiency, and growth.

Dexcom’s AI‑driven CGM strategy, regulatory edge, and emerging market push position it for a 20‑25 % market share by 2030, offering investors a unique growth play.

Dexcom’s CGM trial proves non‑insulin type‑2 patients gain better control, satisfaction and lower A1C—unlocking new revenue, reimbursement and market growth.

Dexcom’s executive share sale shows market dynamics but won’t change its strong growth, competitive edge, or patient‑centric strategy in CGM technology.

Dexcom’s insider sale and May 2026 market surge show robust governance and steady growth in digital health, highlighting resilience amid rising rates.

DexCom’s latest Form 4 filing shows executive share sales and robust CGM revenue growth, highlighting strong market performance, operational challenges, and a focus on value‑based reimbursement in the diabetes‑care sector.

Dexcom’s latest CGM tech, FDA‑cleared and improving patient adherence, boosts its stock and fuels a disciplined share‑sale strategy for future growth.

Dexcom shares jump after appointing two independent directors and renaming its technology committee, boosting investor confidence in its governance and growth strategy.